AGTC to Present at Upcoming Virtual Conferences
Applied Genetic Technologies Corporation (Nasdaq: AGTC) has announced its participation in two upcoming virtual conferences in October 2020.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Applied Genetic Technologies Corporation (Nasdaq: AGTC) has announced its participation in two upcoming virtual conferences in October 2020. The first is the Alliance for Regenerative Medicine Cell & Gene Meeting on the Mesa, occurring from October 12-16, where CEO Sue Washer will present on-demand. The second event is the Dry AMD Therapeutic Development Summit on October 28-29, featuring CSO Mark Shearman in a panel discussion on dry AMD patient treatment. AGTC focuses on gene therapies for rare diseases, with clinical trials for inherited retinal diseases.
Details
News Market Reaction – AGTC
The recorded move for AGTC in the trading session of this news was +0.55%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Oct. 08, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company focused on developing adeno-associated virus (AAV) based gene therapies for the treatment of rare inherited diseases, today announced that management will participate in the following virtual conferences:
- Alliance for Regenerative Medicine Cell & Gene Meeting on the Mesa (October 12-16, 2020)
A company presentation by Sue Washer, President & Chief Executive Officer, will be available for registered attendees to view on-demand throughout the entirety of the conference. Please visit www.meetingonthemesa.com for full information including registration.
- Dry AMD Therapeutic Development Summit (October 28-29, 2020)
Mark Shearman, Chief Scientific Officer, will participate in a panel discussion titled “Defining the Therapeutic Journey for Dry AMD Patients” at 9:15 a.m. ET on Wednesday, October 28, 2020. Please visit www.dry-amd-therapeutics.com for full information including registration.
About AGTC
AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies that address real patient needs. The Company’s most advanced clinical programs leverage its best-in-class technology platform to potentially improve vision for patients with an inherited retinal disease. AGTC has active clinical trials in X-linked retinitis pigmentosa and achromatopsia (ACHM CNGB3 & ACHM CNGA3). Its pre-clinical programs build on the Company’s industry leading AAV manufacturing technology and scientific expertise. AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders.
IR/PR CONTACTS:
David Carey (IR) or Glenn Silver (PR)
Lazar FINN Partners
T: (212) 867-1768 or (646) 871-8485
david.carey@finnpartners.com or glenn.silver@finnpartners.com
Corporate Contact:
Bill Sullivan
Chief Financial Officer
Applied Genetic Technologies Corporation
T: (617) 843-5728
bsullivan@agtc.com
Stephen Potter
Chief Business Officer
Applied Genetic Technologies Corporation
T: (617) 413-2754
spotter@agtc.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.